Relative Bioavailability of Empagliflozin 5 mg BID vs 10 mg QD

Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t up to 168 hours, Area under the concentration-time curves of the analyte in plasma at steady-state over two dosing intervals up to 168 hours and 1 more. Started Sep 2009; status: completed.